Coinfection
EACS 2017: Hepatitis C Halved among Spanish People with HIV Thanks to HCV Treatment
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 31 October 2017 00:00
- Written by Keith Alcorn
Spain is making dramatic progress towards eliminating hepatitis C among people living with HIV because of widespread use of direct-acting antivirals, Juan Berenguer of Hospital Gregorio Marañón in Madrid reported last week at the 16th European AIDS Conference (EACS 2017) in Milan.
CROI 2017: Higher than Expected HCV Prevalence Among HIV- Gay Men in Amsterdam PrEP Program
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 22 March 2017 00:00
- Written by Liz Highleyman
An unexpectedly high number of HIV-negative gay and bisexual men taking pre-exposure prophylaxis (PrEP) in Amsterdam were found to have hepatitis C virus (HCV) infection, suggesting HCV is being transmitted sexually between men with and without HIV, according to a presentation last month at the Conference on Retroviruses and Opportunistic Infections in Seattle.
Improved HIV Treatment Has Not Reduced End-Stage Liver Disease in HIV/HCV Coinfected People
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 19 October 2016 00:00
- Written by Michael Carter
Incidence of end-stage liver disease (ESLD) among HIV-positive people with viral hepatitis changed little between 1996 and 2010, despite major improvements in HIV treatment and care, investigators from Canada and the U.S. report in the November 1 edition of Clinical Infectious Diseases.
CROI 2017: DAA Therapy Cures HIV/HCV Coinfected People with Decompensated Cirrhosis or Transplants
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 08 March 2017 00:00
- Written by Liz Highleyman
HIV/HCV coinfected people with liver cirrhosis or liver failure, and those who received liver transplants, saw high rates of sustained virological response using interferon-free direct-acting antiviral (DAA) therapy for hepatitis C, according to 3 Spanish studies presented at the Conference on Retroviruses and Opportunistic Infections last month in Seattle.
AIDS 2016: Ongoing Hepatitis B Virus Replication Raises Mortality for People with HIV
- Details
- Category: HIV/HBV Coinfection
- Published on Thursday, 04 August 2016 00:00
- Written by Liz Highleyman
People with HIV and hepatitis B virus (HBV) coinfection have more than double the risk of death if they have ongoing high-level HBV replication, indicating a need for prompt treatment, according to an analysis from the Temprano trial presented at an HIV and viral hepatitis coinfection session at the 21st International AIDS Conference (AIDS 2016) last month in Durban.
AASLD 2016: Sofosbuvir/ Ledipasvir Effective for HIV/HCV Coinfected People in Real-World Cohorts
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 22 November 2016 00:00
- Written by Liz Highleyman
The sofosbuvir/ledipasvir (Harvoni) coformulation used in real-world clinical practice produced good sustained virological response rates similar to those seen in clinical trials for HIV-positive people coinfected with hepatitis C, according to a pooled analysis presented at the 2016 AASLD Liver Meeting this month in Boston.
AIDS 2016: AbbVie 3D and 2D Hepatitis C Combos Work Well for HIV/HCV Coinfected People
- Details
- Category: HIV/HCV Coinfection
- Published on Friday, 29 July 2016 00:00
- Written by Liz Highleyman
AbbVie's paritaprevir-based 3D regimen for hepatitis C virus (HCV) genotype 1 and 2D regimen for genotype 4 were shown to be highly effective and well-tolerated for HIV-positive people with HCV coinfection in the TURQUOISE-I trial, according to a report at the 21st International AIDS Conference last week in Durban.
AASLD 2016: HIV/HCV Coinfected People See Good Cure Rates in Real-World Practice in Madrid
- Details
- Category: HIV/HCV Coinfection
- Published on Monday, 21 November 2016 00:00
- Written by Liz Highleyman
More than 90% of HIV-positive people treated with direct-acting antivirals for hepatitis C -- including many with liver cirrhosis -- achieved sustained virological response and few discontinued treatment due to side effects, showing that real-world clinical practice can produce results as good as those seen in formal clinical trials, according to results from a Spanish study presented at the AASLD Liver Meeting this month in Boston.
AIDS 2016: Sofosbuvir/ Velpatasvir Shows High Cure Rate in HIV/HCV Coinfection Study
- Details
- Category: HIV/HCV Coinfection
- Published on Thursday, 21 July 2016 00:00
- Written by Liz Highleyman
The once-daily coformulation of sofosbuvir and velpatasvir was highly effective against all hepatitis C virus (HCV) genotypes and was safe and well tolerated by HIV/HCV coinfected patients in the ASTRAL-5 trial, according to results presented at the 21st International AIDS Conference (AIDS 2016)this week in Durban. A related analysis showed that sofosbuvir/velpatasvir can be safely combined with most widely used antiretrovirals, with the exception of efavirenz.
Web Design and Development by